臨床泌尿器科69巻12号

2015年11月発行

特集 いまさら聞けない！泌尿器がん化学療法の理論と実践 Ⅳ．疾患別がん化学療法の理論と実践

腎がん

著者： 金容壱¹

所属機関： ¹聖隷浜松病院化学療法科

ページ範囲：P.1036 - P.1040

要旨　治療のパラダイムが変化しつつある腎細胞がんであるが，現時点では分子標的薬が薬物療法の主力である。特徴的な有害事象の出現に備えつつ適切に薬物療法を継続することで，QOLの維持と生命予後の延長が得られる。

参考文献

1）Klapper JA, Downey SG, Smith FO, et al：High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma：a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113：293-301, 2008

2）Childs R, Chernoff A, Contentin N, et al：Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343：750-758, 2000

3）Tykodi SS, Sandmaier BM, Warren EH, et al：Allogeneic hematopoietic cell transplantation for renal cell carcinoma：ten years after. Expert Opin Biol Ther 11：763-773, 2011

4）Wahlgren T, Harmenberg U, Sandström P, et al：Treatment and overall survival in renal cell carcinoma：a Swedish population-based study（2000-2008）. Br J Cancer 108：1541-1549, 2013

5）Haas NB, Manola J, Robert G, et al：Initial results from ASSURE（E2805）：Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase Ⅲ trial. Proc ASCO 2015 #403

6）Elhilali MM, Gleave M, Fradet Y, et al：Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 86：613-618, 2000

7）Flanigan RC, Salmon SE, Blumenstein BA, et al：Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345：1655-1659, 2001

8）Mickisch GH, Garin A, van Poppel H, et al：Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma：a randomised trial. Lancet 358：966-970, 2001

9）Motzer RJ, Hutson TE, Tomczak P, et al：Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27：3584-3590, 2009

10）Motzer RJ, Hutson TE, Cella D, et al：Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369：722-731, 2013

11）Escudier B, Eisen T, Stadler WM, et al：Sorafenib for treatment of renal cell carcinoma：Final efficacy and safety results of the phase Ⅲ treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27：3312-3318, 2009

12）Escudier B, Szczylik C, Hutson TE, et al：Randomized phase Ⅱ trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27：1280-1289, 2009

13）Hutson TE, Lesovoy V, Al-Shukri S, et al：Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma：a randomised open-label phase 3 trial. Lancet Oncol 14：1287-1294, 2013

14）Hudes G, Carducci M, Tomczak P, et al：Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356：2271-2281, 2007

15）Motzer RJ, Barrios CH, Kim TM, et al：Phase Ⅱ Randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32：2765-2772, 2014

16）Rini BI, Escudier B, Tomczak P, et al：Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma（AXIS）：a randomised phase 3 trial. Lancet 378：1931-1939, 2011

17）Motzer RJ, Escudier B, Oudard S, et al：Phase 3 trial of everolimus for metastatic renal cell carcinoma：final results and analysis of prognostic factors. Cancer 116：4256-4265, 2010

18）Hutson TE, Escudier B, Esteban E, et al：Randomized phase Ⅲ trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32：760-767, 2014

19）Oudard S, Banu E, Vieillefond A, et al：Prospective multicenter phase Ⅱ study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma：results of a GETUG（Groupe d'Etudes des Tumeurs Uro-Génitales）study. J Urol 177：1698-1702, 2007

20）Vera-Badillo FE, Templeton AJ, Duran I, et al：Systemic therapy for non-clear cell renal cell carcinomas：a systematic review and meta-analysis. Eur Urol 67：740-749, 2015

21）Tannir NM, Jonasch E, Altinmakas E, et al：Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma（The ESPN Trial）：A multicenter randomized phase 2 trial. Proc ASCO 2014 #4505

22）Armstrong AJ, Broderick S, Eisen T, et al：Final clinical results of a randomized phase Ⅱ international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma（ASPEN）. Proc ASCO 2015 #4507